Skip to main content
ArticleOPEN ACCESS

Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al

Arthritis Research and Therapy
DOI: 10.1186/ar2026
44Citations
Citations of this article
39Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

A recent meta-analysis of randomized clinical trials reported by Bongartz and coworkers raised concerns about an increased rate of malignancy and serious infection in rheumatoid arthritis patients treated with anti-tumour necrosis factor monoclonal antibodies. This commentary discusses some of the methodological issues in their analysis and urges caution in interpreting the results. © 2006 BioMed Central Ltd.

Cite

CITATION STYLE

APA

Dixon, W., & Silman, A. (2006, October). Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al. Arthritis Research and Therapy. https://doi.org/10.1186/ar2026

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free